Company Description
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally.
It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve.
In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient’s heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure.
The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
| Country | United States |
| Founded | 1958 |
| IPO Date | Mar 27, 2000 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 19,800 |
| CEO | Bernard Zovighian |
Contact Details
Address: One Edwards Way Irvine, California 92614 United States | |
| Phone | 949 250 2500 |
| Website | edwards.com |
Stock Details
| Ticker Symbol | EW |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001099800 |
| CUSIP Number | 28176E108 |
| ISIN Number | US28176E1082 |
| Employer ID | 36-4316614 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Bernard J. Zovighian | Chief Executive Officer and Director |
| Scott B. Ullem | Corporate Vice President and Chief Financial Officer |
| Donald E. Bobo Jr. | Corporate Vice President of Strategy and Corporate Development |
| Larry L. Wood | Corporate Vice President and Group President of TAVR and Surgical Structural Heart |
| Andrew M. Dahl | Principal Accounting Officer, Senior Vice President and Corporate Controller |
| Dr. Todd J. Brinton FACC, M.D. | Corporate Vice President of Advanced Technology and Chief Scientific Officer |
| Mark Wilterding | Vice President of Investor Relations |
| Dirksen J. Lehman | Corporate Vice President of Public Affairs |
| Christine Z. McCauley | Corporate Vice President of Human Resources |
| Gary I. Sorsher | Senior Vice President of Quality and Regulatory Compliance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | 144 | Filing |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 5, 2024 | 144 | Filing |
| Oct 24, 2024 | 8-K | Current Report |
| Oct 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 3, 2024 | 8-K | Current Report |
| Aug 20, 2024 | 144 | Filing |
| Aug 14, 2024 | 144 | Filing |
| Jul 31, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |